Latest news with #Q4results
Yahoo
4 days ago
- Business
- Yahoo
Elastic price target lowered to $110 from $135 at Wedbush
Wedbush analyst Daniel Ives lowered the firm's price target on Elastic (ESTC) to $110 from $135 and keeps an Outperform rating on the shares. The firm notes Elastic delivered its Q4 results featuring strong beats on the top and bottom line, which will be largely overshadowed by FY26 revenue guidance that came in below Street expectations as enterprises are increasingly integrating GenAI into their operations, while the company is seeing more consumption scrutiny due to the murky macro. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ESTC: Disclaimer & DisclosureReport an Issue Elastic price target lowered to $92 from $109 at Cantor Fitzgerald Guggenheim lowers Elastic price target, recommends buying on weakness Elastic price target lowered to $115 from $125 at Baird Elastic price target lowered to $112 from $140 at Stifel Elastic price target lowered to $115 from $120 at Morgan Stanley Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Canopy Growth Corp (CGC) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Canada Net Revenue: $40 million in Q4, up 4% year-over-year. Canada Medical Sales Growth: 13% increase versus last year. Canada Adjusted Gross Margin: 11% in Q4; adjusted cash gross margin at 23%. International Markets Sales Decline: 35% decrease in Q4 fiscal '25 compared to Q4 fiscal '24. Storz & Bickel Revenue: $17 million in Q4, down 23% year-over-year. SG&A Expenses: Declined 28% year-over-year. Q4 Adjusted EBITDA Loss: $9 million, an improvement from a $15 million loss a year ago. Free Cash Flow: Outflow of $36 million in Q4; full year outflow of $177 million. Cash and Short-term Investments: $131 million as of March 31, 2025. Total Principal Debt Balance: $316 million as of March 31, 2025. Canopy USA Annualized Revenue: Approximately USD 210 million. Cost Reduction Target: At least $20 million over the next 12 to 18 months. Warning! GuruFocus has detected 4 Warning Signs with CGC. Release Date: May 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Canopy Growth Corp (NASDAQ:CGC) has unified its global medical cannabis businesses to improve speed, scalability, and market responsiveness, leading to a 13% growth in the Canadian medical business. The company has streamlined its Canadian adult-use business by removing low-performing SKUs and focusing on high-margin products, which has strengthened relationships with key accounts. Canopy Growth Corp (NASDAQ:CGC) has established a centralized global operations function to enhance supply and demand planning, resulting in improved fill rates from mid-80s to mid-90s. The company has identified $20 million in cost reductions, with 80% of savings already identified and over 50% executed, creating financial flexibility for reinvestment. Canopy Growth Corp (NASDAQ:CGC) has made a USD100 million early prepayment on its senior secured term loan, reducing annual interest expenses by approximately USD13 million. Q4 fiscal '25 results fell short of expectations due to lower revenue in Storz & Bickel, Poland, and Australian medical businesses. Free cash flow was an outflow of $36 million for Q4, compared to an outflow of $23 million a year ago, due to higher capex and increased working capital. International markets cannabis sales declined 35% in Q4 fiscal '25 compared to Q4 fiscal '24, with significant drops in Poland and Australia. Storz & Bickel experienced a 23% year-over-year revenue decline in Q4, with continued softness into Q1 fiscal '26 due to decreased vaporizer demand. Acreage's performance was negatively impacted by liquidity challenges and underperformance in the Ohio adult-use cannabis market, affecting Canopy USA's revenue expectations. Q: Can you provide more color on near-term opportunities versus long-term actions to achieve positive adjusted EBITDA? A: Luc Mongeau, CEO: We're focusing on cost reductions and growth, particularly in our medical business, which is performing well in Canada. We've streamlined operations and are focusing on high-potential areas like Canadian REC and medical cannabis in Europe and Australia. Our goal is to capitalize on near-term opportunities with the highest potential returns. Q: What makes the current streamlining and cost-saving initiatives different from past efforts? A: Luc Mongeau, CEO: The current actions are about fundamentally transforming the organization into focused, streamlined business units with centralized core capabilities. We've eliminated layers of management to speed up decision-making and empower teams, which is a significant cultural shift from past approaches. Q: What factors have contributed to Acreage's underperformance, and what is the outlook for Canopy USA? A: Judy Hong, CFO: Acreage's challenges stem from liquidity issues and underperformance in Ohio, which hasn't fully opened as an adult-use market. This has impacted their ability to invest in other core markets. Despite these challenges, we remain optimistic about the long-term potential of the US market. Q: How are you addressing supply chain inconsistencies, especially for international markets? A: Luc Mongeau, CEO: We've centralized our supply chain and sales operations to improve decision-making and resource allocation. This restructuring allows us to better manage cultivation and distribution, ensuring consistent supply without needing significant new investments. Q: Can you provide insights into the Canadian medical cannabis market and Canopy's performance? A: Judy Hong, CFO: The Canadian medical market is declining slightly, but we've outperformed with a 16% growth, gaining market share. Our focus is on high-value patients and providing excellent customer experiences, which we aim to leverage in international markets as well. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
5 days ago
- Business
- Yahoo
Canopy Growth Corp (CGC) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Canada Net Revenue: $40 million in Q4, up 4% year-over-year. Canada Medical Sales Growth: 13% increase versus last year. Canada Adjusted Gross Margin: 11% in Q4; adjusted cash gross margin at 23%. International Markets Sales Decline: 35% decrease in Q4 fiscal '25 compared to Q4 fiscal '24. Storz & Bickel Revenue: $17 million in Q4, down 23% year-over-year. SG&A Expenses: Declined 28% year-over-year. Q4 Adjusted EBITDA Loss: $9 million, an improvement from a $15 million loss a year ago. Free Cash Flow: Outflow of $36 million in Q4; full year outflow of $177 million. Cash and Short-term Investments: $131 million as of March 31, 2025. Total Principal Debt Balance: $316 million as of March 31, 2025. Canopy USA Annualized Revenue: Approximately USD 210 million. Cost Reduction Target: At least $20 million over the next 12 to 18 months. Warning! GuruFocus has detected 4 Warning Signs with CGC. Release Date: May 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Canopy Growth Corp (NASDAQ:CGC) has unified its global medical cannabis businesses to improve speed, scalability, and market responsiveness, leading to a 13% growth in the Canadian medical business. The company has streamlined its Canadian adult-use business by removing low-performing SKUs and focusing on high-margin products, which has strengthened relationships with key accounts. Canopy Growth Corp (NASDAQ:CGC) has established a centralized global operations function to enhance supply and demand planning, resulting in improved fill rates from mid-80s to mid-90s. The company has identified $20 million in cost reductions, with 80% of savings already identified and over 50% executed, creating financial flexibility for reinvestment. Canopy Growth Corp (NASDAQ:CGC) has made a USD100 million early prepayment on its senior secured term loan, reducing annual interest expenses by approximately USD13 million. Q4 fiscal '25 results fell short of expectations due to lower revenue in Storz & Bickel, Poland, and Australian medical businesses. Free cash flow was an outflow of $36 million for Q4, compared to an outflow of $23 million a year ago, due to higher capex and increased working capital. International markets cannabis sales declined 35% in Q4 fiscal '25 compared to Q4 fiscal '24, with significant drops in Poland and Australia. Storz & Bickel experienced a 23% year-over-year revenue decline in Q4, with continued softness into Q1 fiscal '26 due to decreased vaporizer demand. Acreage's performance was negatively impacted by liquidity challenges and underperformance in the Ohio adult-use cannabis market, affecting Canopy USA's revenue expectations. Q: Can you provide more color on near-term opportunities versus long-term actions to achieve positive adjusted EBITDA? A: Luc Mongeau, CEO: We're focusing on cost reductions and growth, particularly in our medical business, which is performing well in Canada. We've streamlined operations and are focusing on high-potential areas like Canadian REC and medical cannabis in Europe and Australia. Our goal is to capitalize on near-term opportunities with the highest potential returns. Q: What makes the current streamlining and cost-saving initiatives different from past efforts? A: Luc Mongeau, CEO: The current actions are about fundamentally transforming the organization into focused, streamlined business units with centralized core capabilities. We've eliminated layers of management to speed up decision-making and empower teams, which is a significant cultural shift from past approaches. Q: What factors have contributed to Acreage's underperformance, and what is the outlook for Canopy USA? A: Judy Hong, CFO: Acreage's challenges stem from liquidity issues and underperformance in Ohio, which hasn't fully opened as an adult-use market. This has impacted their ability to invest in other core markets. Despite these challenges, we remain optimistic about the long-term potential of the US market. Q: How are you addressing supply chain inconsistencies, especially for international markets? A: Luc Mongeau, CEO: We've centralized our supply chain and sales operations to improve decision-making and resource allocation. This restructuring allows us to better manage cultivation and distribution, ensuring consistent supply without needing significant new investments. Q: Can you provide insights into the Canadian medical cannabis market and Canopy's performance? A: Judy Hong, CFO: The Canadian medical market is declining slightly, but we've outperformed with a 16% growth, gaining market share. Our focus is on high-value patients and providing excellent customer experiences, which we aim to leverage in international markets as well. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
Eris Lifesciences Ltd (NSE:ERIS) Q4 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...
Release Date: May 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Eris Lifesciences Ltd (NSE:ERIS) reported a 28% year-on-year growth in consolidated operating revenue for Q4, reaching INR 705 crores. The company achieved a significant 70% year-on-year growth in consolidated EBITDA, amounting to INR 252 crores. Eris Lifesciences Ltd (NSE:ERIS) saw a 28% growth in profit after tax, totaling INR 102 crores for the quarter. The company reported a strong operating cash flow to EBITDA ratio of 111% in Q4. The return on capital employed (ROCE) improved to 15% for FY25, up from 11% in the previous year, with an adjusted ROCE of 20%. There was a significant product shortage in human insulin, resulting in an estimated sales loss of around INR 50 crores. The critical care segment experienced a planned 20% decline, attributed to delays in building out the domestic go-to-market strategy. The company faced challenges in the oncology business due to product mix issues, impacting performance. Insulin fill-in took longer than anticipated, affecting the rollout of certain products. The company experienced intermittent connection issues during the earnings call, leading to unclear communication at times. Warning! GuruFocus has detected 8 Warning Signs with NSE:ERIS. Q: Can you clarify the impact of the supply shortage on the insulin business and the expected market capture? A: We experienced a sales loss of around INR 50 crore due to supply shortages, with INR 38 crore within the Biocon One business. We are confident in capturing 50-60% of the vacated market, supported by a secured supply deal and upcoming capacity expansions. (Respondent: Unidentified_3) Q: What are the challenges faced in the critical care business, and how do you plan to address them? A: The critical care segment faced issues due to a lack of market strategy and bandwidth. We are working on improving our go-to-market strategy and expect to see improvements in the next quarter. (Respondent: Unidentified_3) Q: Why is there a discrepancy in the expected margin improvements despite significant growth in the insulin business? A: The expected margin improvements are tempered by the timing of cartridge production, which will start in Q4, and the addition of 300 new employees, which initially strains the EBITDA line. We are cautiously guiding a 37% margin. (Respondent: Unidentified_3) Q: How does Eris plan to fill the gap left by Novo's exit from the insulin cartridge market? A: We believe the substitutes offered by Novo are either reverting to vials or are significantly more expensive. We expect to capture a significant portion of the market due to our competitive pricing and established brands. (Respondent: Unidentified_3) Q: What are the next steps for Swiss Parentals in terms of export opportunities and CDMO contracts? A: We are awaiting N visa approval, which will open large markets for us. We are in discussions for CDMO contracts, focusing on specialty injectables for EU clients, with plans to expand into oral solids. (Respondent: Unidentified_3) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
